参考文献/References:
[1] Botton MR,Whirl-Carrillo M,Del Tredici AL,et al. PharmVar GeneFocus:CYP2C19[J]. Clin Pharmacol Ther,2021,109(2):352-366.
[2] Scott SA,Sangkuhl K,Shuldiner AR,et al. PharmGKB summary:very important pharmacogene information for cytochrome P450,family 2,subfamily C,polypeptide 19[J]. Pharmacogenet Genomics,2012,22(2):159-165.
[3] Steinhubl SR,Berger PB,Mann JR 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J]. JAMA,2002,288(19):2411-2420.
[4] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 抗血小板治疗中国专家共识[J]. 中华心血管病杂志,2013,41(3):183-194.
[5] Lewis JP,Backman JD,Reny JL,et al. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients[J]. Eur Heart J Cardiovasc Pharmacother,2020,6(4):203-210.
[6] Verma SS,Bergmeijer TO,Gong L,et al. Genomewide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel:a study by the international clopidogrel p harmacogenomics consortium[J]. Clin Pharmacol Ther,2020,108(5):1067-1077.
[7] Goldstein JA,de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily[J]. Pharmacogenetics,1994,4(6):285-299.
[8] Zhou SF,Liu JP,Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact[J]. Drug Metab Rev,2009,41(2):89-295.
[9] Lee CR,Luzum JA,Sangkuhl K,et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy:2022 update[J]. Clin Pharmacol Ther,2022,112(5):959-967.
[10] Scott SA,Sangkuhl K,Gardner EE,et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19(CYP2C19) genotype and clopidogrel therapy[J]. Clin Pharmacol Ther,2011,90(2):328-332.
[11] Desta Z,Zhao X,Shin JG,et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism[J]. Clin Pharmacokinet,2002,41(12):913-958.
[12] Coccheri S. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors[J]. Drugs,2010,70(7):887-908.
[13] Kazui M,Nishiya Y,Ishizuka T,et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos,2010,38(1):92-99.
[14] 单清,孙安修. 质子泵抑制剂预防性应用专家共识(2018)[J]. 中国医师杂志,2018,20(12):1775-1781.
[15] Geisler T,Langer H,Wydymus M,et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation[J]. Eur Heart J,2006,27(20):2420-2425.
[16] Spiliopoulos S,Pastromas G,Diamantopoulos A,et al. Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures[J]. Expert Opin Pharmacother,2014,15(15):2205-2217.
[17] Le Quellec S,Bordet JC,Negrier C,et al. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature[J]. Thromb Haemost,2016,116(4):638-650.
[18] Breet NJ,van Werkum JW,Bouman HJ,et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation[J]. JAMA,2010,303(8):754-762.
[19] Zhang Y,Chou JW,Huang WT,et al. Platelet reactivity testing in peripheral artery disease[J]. Am J Health Syst Pharm,2022,79(16):1312-1322.
[20] Aradi D,Storey RF,Komócsi A,et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention[J]. Eur Heart J,2014,35(4):209-215.
[21] Gross L,Aradi D,Sibbing D. Platelet function testing in patients on antiplatelet medications[J]. Semin Thromb Hemost,2016,42(3):306-320.
[22] Wallentin L,James S,Storey RF,et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial[J]. Lancet,2010,376(9749):1320-1328.
[23] Mehran R,Baber U,Sharma SK,et al. Ticagrelor with or without aspirin in high-risk patients after PCI[J]. N Engl J Med,2019,381(21):2032-2042.
[24] Hiatt WR,Fowkes FG,Heizer G,et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease[J]. N Engl J Med,2017,376(1):32-40.
[25] Tsigkou V,Siasos G,Rovos K,et al. Peripheral artery disease and antiplatelet treatment[J]. Curr Opin Pharmacol,2018,39:43-52.
[26] Varenhorst C,James S,Erlinge D,et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease[J]. Eur Heart J,2009,30(14):1744-1752.
[27] Lin Y,Cai Z,Dong S,et al. Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention:a network meta-analysis of randomized controlled trials[J]. Front Pharmacol ,2022,13:992376.
[28] Kim HS,Kang J,Hwang D,et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS):an open-label,multicentre,non-inferiority randomised trial[J]. Lancet,2020,396(10257):1079-1089.
[29] Lee CR,Thomas CD,Beitelshees AL,et al. Impact of the CYP2C19*17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention[J]. Clin Pharmacol Ther,2021,109(3):705-715.
[30] Shuldiner AR,O’Connell JR,Bliden KP,et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. JAMA,2009,302(8):849-857.
[31] Dayoub EJ,Seigerman M,Tuteja S,et al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary i ntervention,2008-2016[J]. JAMA Intern Med,2018,178(7):943-950.
[32] Gimbel M,Qaderdan K,Willemsen L,et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE):the randomised, open-label ,non-inferiority trial[J]. Lancet,2020,395(10233):1374-1381.
[33] Collet JP,Thiele H,Barbato E,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2021,42(14):1289-1367.
[34] Amsterdam EA,Wenger NK,Brindis RG,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2014,130(25):e344-e426.
[35] Galli M,Benenati S,Capodanno D,et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention:a systematic review and meta-analysis[J]. Lancet,2021,397(10283):1470-1483.
[36] Galli M,Benenati S,Franchi F,et al. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome:a network meta-analysis of 61898 patients from 15 randomized trials[J]. Eur Heart J,2022,43(10):959-967.
[37] Claassens DMF,Vos GJA,Bergmeijer TO,et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI[J]. N Engl J Med,2019,381(17):1621-1631.
[38] Tuteja S,Glick H,Matthai W,et al. Prospective CYP2C19 genotyping to guide antiplatelet therapy following percutaneous coronary intervention:a pragmatic randomized clinical trial[J]. Circ Genom Precis Med,2020,13(1):e002640.
[39] Pereira NL,Farkouh ME,So D,et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary i ntervention:the TAILOR-PCI randomized clinical trial[J]. JAMA,2020,324(8):761-771.
[40] Zheng YY,Wu TT,Yang Y,et al. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention:a randomized controlled clinical trial[J]. Eur Heart J Cardiovasc Pharmacother,2020,6(4):211-221.
[41] Xiong Y,Bath PM. Antiplatelet therapy for transient ischemic attack and minor stroke[J]. Stroke,2020,51(11):3472-3474.
[42] Bath PM,Woodhouse LJ,Appleton JP,et al. Antiplatelet therapy with aspirin,clopidogrel,and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS):a randomised,open-label,phase 3 superiority trial[J]. Lancet,2018,391(10123):850-859.
[43] Wang Y,Meng X,Wang A,et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med,2021,385(27):2520-2530.
[44] Liuzzo G,Patrono C. Give genotype-guided dual antiplatelet therapy a second CHANCE[J]. Eur Heart J,2022,43(10):938-939.
[45] Pan Y,Meng X,Jin A,et al. Time course for benefit and risk with ticagrelor and aspirin in individuals with acute ischemic stroke or transient ischemic attack who carry CYP2C19 l oss-of-function alleles:a secondary analysis of the CHANCE-2 randomized clinical trial[J]. JAMA Neurol,2022,79(8):739-745.
[46] Wang A,Meng X,Tian X,et al. Ticagrelor aspirin vs clopidogrel aspirin in CYP2C19 loss-of-function carriers with minor stroke or TIA stratified by risk profile[J]. Neurology,2023,100(5):e497-e504.
[47] Pan Y,Chen W,Xu Y,et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack:a systematic review and meta-analysis[J]. Circulation,2017,135(1):21-33.
[48] Foley TR,Waldo SW,Armstrong EJ. Antithrombotic therapy in peripheral artery disease[J]. Vasc Med,2016,21(2):156-169.
[49] Berger JS,Krantz MJ,Kittelson JM,et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease:a meta-analysis of randomized trials[J]. JAMA,2009,301(18):1909-1919.
[50] Fowkes FG,Price JF,Stewart MC,et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index:a randomized controlled trial[J]. JAMA,2010,303(9):841-848.
[51] Belch J,MacCuish A,Campbell I,et al. The prevention of progression of arterial disease and diabetes(POPADAD) trial:factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease[J]. BMJ,2008,337:a1840.
[52] Jones WS,Baumgartner I,Hiatt WR,et al. Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease[J]. Circulation,2017,135(3):241-250.
[53] Lee J,Cheng N,Tai H,et al. CYP2C19 polymorphism is associated with amputation rates in patients taking clopidogrel after endovascular intervention for critical limb ischaemia[J]. Eur J Vasc Endovasc Surg,2019,58(3):373-382.
[54] Kranendonk J,Willems LH,Vijver-Coppen RV,et al. CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease:study design of a randomized controlled trial (GENPAD)[J]. Am Heart J,2022,254:141-148.
[55] Huang S,Yang S,Ly S,et al. Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms:a systematic review[J]. Eur J Clin Pharmacol,2022,78(8):1217-1225.
[56] Levine GN,Bates ER,Blankenship JC,et al. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. Circulation,2011,124(23):e574-e651.
相似文献/References:
[1]周召锋,吴春阳.急性冠状动脉综合征的抗血小板治疗进展[J].心血管病学进展,2015,(5):646.[doi:10.3969/j.issn.1004-3934.2015.05.032]
ZHOU Zhaofeng,WU Chunyang.Development of Antiplatelet Therapy for Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2015,(11):646.[doi:10.3969/j.issn.1004-3934.2015.05.032]
[2]徐俊波 黄刚 蔡琳 刘汉雄 张廷杰.老老年患者抗血小板治疗的循证临床实践[J].心血管病学进展,2019,(8):1123.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.013]
XU Junbo,HUANG Gang,CAI Lin,et al.Evidence-based Antiplatelet Treatment in Very Elderly Patients in Clinical Practice[J].Advances in Cardiovascular Diseases,2019,(11):1123.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.013]
[3]朱志伦 田乃亮.急性冠脉综合征患者抗血小板降阶治疗方案研究进展[J].心血管病学进展,2021,(6):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
ZHU Zhilun,TIAN Nailiang.Advances in De-Escalation of Anti-Platelet Therapy in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(11):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
[4]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(11):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
[5]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(11):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[6]徐蓉玮 王亚玲.冠状动脉非阻塞性心肌梗死抗血小板治疗作用[J].心血管病学进展,2022,(10):888.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.006]
XU RongweiWANG Yaling.Role of Antiplatelet Therapy in Myocardial Infarction with Non-obstructive Coronary Arteries[J].Advances in Cardiovascular Diseases,2022,(11):888.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.006]
[7]刘娟 熊诗强 蔡琳.经皮冠状动脉介入治疗术后出血风险评估研究进展[J].心血管病学进展,2023,(4):303.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.004]
LIU Juan,XIONG Shiqiang,CAI Lin.Bleeding Risk Assessment After Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2023,(11):303.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.004]
[8]吕易非 李紫凡 邵褀睿 韩江莉.急性冠脉综合征合并高出血风险患者双联抗血小板治疗研究进展[J].心血管病学进展,2023,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
LV Yifei,LI Zifan,SHAO Qirui,et al.Dual Antiplatelet Therapy for Patients with Acute Coronary Syndrome and High Bleeding Risk[J].Advances in Cardiovascular Diseases,2023,(11):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
[9]努尔古丽·玉苏普 古力尼尕尔·麦麦提吐尔孙 陈清杰 艾尔肯·阿吉.急性冠脉综合征合并糖尿病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2023,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]
Nurgul·Yusup,Gulinigar·Mamattursun,CHEN Qingjie,et al.P2Y12 Receptor Antagonist Therapy in A cute Coronary Syndrome with Diabetes[J].Advances in Cardiovascular Diseases,2023,(11):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]